A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid

Status Recruiting

Clinical Trial Summary

This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment options for patients with advanced or metastatic solid tumors that express HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab vedotin is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial uses a drug called tucatinib, which has been approved to treat cancer in the United States and some other countries. This drug is sold under the brand name TUKYSA®. This study will test how safe and how well DV, with or without tucatinib, is for participants with solid tumors. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.

Clinical Trial Description

This clinical trial is to evaluate disitamab vedotin alone and in combination with tucatinib in subjects with LA/metastatic breast cancer or gastric cancer/GEJC that express HER2. The study has a dose escalation phase evaluating disitamab vedotin plus tucatinib followed by a dose optimization phase. The 2 dose levels identified in the dose escalation phase will be assessed in the optimization phase for both safety and efficacy in HER2-low LA/mBC subjects. Once the safety and efficacy profile of disitamab vedotin plus tucatinib has been established and a disitamab vedotin dose with the optimum benefit/risk ratio has been determined the disitamab vedotin plus tucatinib combination therapy will be evaluated in an expansion phase with 2 expansion cohorts in subjects with HER2 low mGC/GEJC and HER2 + LA/mBC. ;

Study Design

Related Conditions & MeSH terms

Breast Neoplasms
Gastroesophageal Junction Adenocarcinoma
Neoplasms
Stomach Neoplasms
Triple Negative Breast Neoplasms

Clinical Trial Details

NCT number	NCT06157892
Study type	Interventional
Source	Seagen Inc.
Contact	Seagen Trial Information Support
Phone	866-333-7436
Email	clinicaltrials@seagen.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	May 20, 2024
Completion date	January 31, 2030

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05558917` - Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery	N/A
Active, not recruiting	`NCT03664778` - Abbreviated Breast MRI After Cancer Treatment
Recruiting	`NCT03144622` - 18F-FSPG PET/CT Imaging in Patients With Cancers
Completed	`NCT05452499` - Pain Neuroscience Education and Therapeutic Exercise as a Treatment for Breast Cancer Survivors Living With Sequelae	N/A
Active, not recruiting	`NCT04568902` - Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer	Phase 1
Completed	`NCT02860585` - Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation	N/A
Completed	`NCT04059809` - Photobiomodulation for Breast Cancer Radiodermatitis	Phase 2/Phase 3
Recruiting	`NCT04557449` - Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors	Phase 1/Phase 2
Completed	`NCT03698942` - Delphinus SoftVue™ ROC Reader Study
Completed	`NCT00092950` - Exercise in Women at Risk for Breast Cancer	Phase 2
Terminated	`NCT04123704` - Sitravatinib in Metastatic Breast Cancer	Phase 2
Not yet recruiting	`NCT02151071` - The Breast Surgery EnLight and LightPath Imaging System Study	Phase 1/Phase 2
Recruiting	`NCT02934360` - TR(ACE) Assay Clinical Specimen Study	N/A
Active, not recruiting	`NCT02950064` - A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations	Phase 1
Not yet recruiting	`NCT02876848` - A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study)	N/A
Completed	`NCT02931552` - Nuevo Amanecer II: Translating a Stress Management Program for Latinas	N/A
Recruiting	`NCT02547545` - Breast Cancer Chemotherapy Risk Prediction Mathematical Model	N/A
Completed	`NCT02303366` - Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475	Phase 1
Completed	`NCT02518477` - Preventive Intervention Against Lymphedema After Breast Cancer Surgery	N/A
Completed	`NCT02652975` - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms